Pharma and Biotech Financial Outlook: Hazy
16 June 2016
The pharma and biotech industries are facing several structural factors specific to the sector itself, as well as external forces that are fostering uncertainty on overall global business and financial conditions. Political risks that could adversely impact investor perceptions about the viability of the industry’s long-term investment cycle are becoming more prominent, especially as the US begins a crucial presidential election season. Both major political parties are in the unprecedented position of challenging the industry’s historical business model based on the premise that high risk justifies high prices.
New Aggressive Treatment Shown to Halt Symptoms of Multiple Sclerosis for a Prolonged Period
16 June 2016
Previous attempts to treat multiple sclerosis (MS), an autoimmune disease characterized by the breakdown of the myelin sheath on axons and axonal degeneration in the central nervous system, have included a regimen of autologous hematopoietic stem-cell transplantation (aHSCT) following chemotherapy. The prevailing thought behind this treatment was to try to re-program the immune system so that it would stop attacking itself. Although this type of treatment has been marked by some successes, many patients experience disease reactivation shortly after treatment.
Leaving EU could be a setback for Life Sciences in the UK
15 June 2016
A vote to leave the EU will have a knock on effect on the life sciences industry, deterring investment and making it harder for patients to access new medicines in the future.
US and EU Regulators Seek to Reduce Pharma Inspections
15 June 2016
As a key step toward reducing the need to inspect every drug production facility in Europe, FDA is looking to share un-redacted inspection reports with trusted European regulatory authorities. More extensive information exchange would help move forward a Mutual Recognition Agreement (MRA) with the European Medicines Agency (EMA), which has been in the works for several years. The aim is to identify facilities with strong records of compliance with GMPs based on inspections by competent local inspectorates.
India mulls easier foreign direct investment in drug companies
15 June 2016
India may allow foreign investors to buy up to 49% of existing drug companies as part of a push by Prime Minister Narendra Modi to liberalize investment rules. Investors would just have to notify the Reserve Bank of India on any transactions.
The price is right? Making the case for innovation
15 June 2016
The headlines always create a stir. A new drug is coming to market with a price tag over $100,000. For consumers, it’s sticker shock. For health plans, an expensive product they weren’t expecting to cover. For skeptical legislators, evidence of an industry in need of tougher pricing controls.
The top companies in med tech: 2015 revenue results
15 June 2016
Med tech companies have found only one reliable way to boost sales--that's to buy them. The only players with sizable sales increases last year were driven by major acquisitions, according to data from Evaluate Medtech.* In fact, only two of the 10 companies as ranked by medical device and diagnostics sales actually had positive sales growth without an acquisition.
State-backed German startup investment vehicle plans new ˆ300M fund
14 June 2016
High-Tech Gründerfonds (HTGF), a seed investor backed by the German government, has revealed plans to raise €300 million ($341 million) for its third fund. The money is intended to enable HTGF to continue the startup-backing remit that has already seen it help 440 companies get off the ground.
Barriers to value-based drug pricing still abound
14 June 2016
America's journey into the tricky landscape of value-based health care, pioneered by hospitals and insurers, continues to beckon drugmakers to get onboard. But logistical difficulties and open questions around who benefits from the approach are slowing its march, panelists said during a session on the subject at the BIO International Convention.
Election year politics a wild card as biopharma weighs financing climate
14 June 2016
The crossover party is all but over. Pure public players have moved upstream. Companies that went public as recently as 2014 are going belly-up. And a hyperbolic presidential election campaign has turned the industry's life-saving mission into a source of public controversy.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Four cancer centers opened in Russia in 2023
26 April 2024
Russia and the UAE can simplify the drug registration process
26 April 2024
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024